During the 2018 Association of Community Cancer Centers National Oncology Conference, Olalekan Oluwole, MBBS, MPH, discusses some of the challenges he has encountered with chimeric antigen receptor T-cell therapy.
During the 2018 Association of Community Cancer Centers National Oncology Conference, Olalekan Oluwole, MBBS, MPH, assistant professor of medicine, division of hematology and oncology, Vanderbilt University Medical Center, discusses some of the challenges he has encountered with chimeric antigen receptor (CAR) T-cell therapy.
Oluwole says that many patients have progressive disease and need chemotherapy while the CAR T-cell therapy is being produced, as their disease tends to grow quickly. Currently, there are 2 commerically-approved products for patients with large B cell lymphoma: axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah). Giving one of these agents to bridge the gap in therapy is a way of keeping the patient's disease controlled while the insurance approval is ongoing or the product is being manufactured.
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
April 16th 2024The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Read More